These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 3149210)
1. Diurnal variation in pharmacokinetics of valproic acid with unequal dosing intervals. Johno I; Nakamura T; Horiuchi T; Nadai M; Kitazawa S; Yoshimine N; Kuzuya F Chem Pharm Bull (Tokyo); 1988 Jul; 36(7):2551-6. PubMed ID: 3149210 [No Abstract] [Full Text] [Related]
2. Chronopharmacokinetics of valproic acid following constant-rate administration in mice and influence of feeding schedule. Song JG; Ohdo S; Ogawa N Zhongguo Yao Li Xue Bao; 1995 Mar; 16(2):113-7. PubMed ID: 7597908 [TBL] [Abstract][Full Text] [Related]
3. Circadian variation of Valproic acid pharmacokinetics in mice. Ben-Cherif W; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA Eur J Pharm Sci; 2013 Jul; 49(4):468-73. PubMed ID: 23707469 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration. Dutta S; Reed RC; Cavanaugh JH Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635 [TBL] [Abstract][Full Text] [Related]
6. Drugs pharmacokinetics in ICU patients: consequences of hypoalbuminemia upon drugs monitoring and dosing scheme. Lagneau F; Perbet S; Delefosse D; Wernet A; Stocco J; Marty J Intensive Care Med; 2004 Jun; 30(6):1247. PubMed ID: 15138675 [No Abstract] [Full Text] [Related]
7. No pharmacokinetic interaction between lacosamide and valproic acid in healthy volunteers. Cawello W; Bonn R J Clin Pharmacol; 2012 Nov; 52(11):1739-48. PubMed ID: 22162508 [TBL] [Abstract][Full Text] [Related]
8. [Detailed monitoring of valproic acid and phenobarbital in the treatment of epilepsy in children]. Sobaniec W; Jankowicz E; Czerwińska-Ciechan K Neurol Neurochir Pol; 1988; 22(5):413-20. PubMed ID: 3150521 [TBL] [Abstract][Full Text] [Related]
9. Efficacy testing of valproic acid compared to ethosuximide in monkey model: I. Dosage regimen design in the presence of diurnal oscillations. Levy RH; Lockard JS; Patel IH; Lai AA Epilepsia; 1977 Jun; 18(2):191-203. PubMed ID: 406138 [No Abstract] [Full Text] [Related]
10. [Inequality of bioavailability in commercial tablets of valproic acid]. Koide N; Abe M No To Hattatsu; 1990 Sep; 22(5):516-7. PubMed ID: 2223193 [No Abstract] [Full Text] [Related]
11. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Ragueneau-Majlessi I; Levy RH; Brodie M; Smith D; Shah J; Grundy JS Clin Pharmacokinet; 2005; 44(5):517-23. PubMed ID: 15871637 [TBL] [Abstract][Full Text] [Related]
12. Circadian variation in anticonvulsant activity of valproic acid in mice. Khedhaier WBC; Dridi I; Aouam K; Ben-Attia M; Reinberg A; Boughattas NA Biomed Pharmacother; 2017 Nov; 95():25-30. PubMed ID: 28826093 [TBL] [Abstract][Full Text] [Related]
13. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients. Miljković B; Pokrajac M; Varagić V; Lević Z Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700 [TBL] [Abstract][Full Text] [Related]
14. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents. Steinborn B; Galas-Zgorzalewicz B Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261 [TBL] [Abstract][Full Text] [Related]
15. Real-time, in vivo monitoring and pharmacokinetics of valproic acid via a novel biomarker in exhaled breath. Gamez G; Zhu L; Disko A; Chen H; Azov V; Chingin K; Krämer G; Zenobi R Chem Commun (Camb); 2011 May; 47(17):4884-6. PubMed ID: 21373707 [TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens. Methaneethorn J Clin Ther; 2017 Jun; 39(6):1171-1181. PubMed ID: 28483293 [TBL] [Abstract][Full Text] [Related]